Literature DB >> 27418105

Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages.

Anne-Laure Chéné1, Sènan d'Almeida2, Thibaut Blondy1, Julie Tabiasco3, Sophie Deshayes1, Jean-François Fonteneau1, Laurent Cellerin4, Yves Delneste5, Marc Grégoire1, Christophe Blanquart6.   

Abstract

INTRODUCTION: Mesothelioma is a rare and aggressive cancer related to asbestos exposure. We recently showed that pleural effusions (PEs) from patients with mesothelioma contain high levels of the C-C motif chemokine ligand 2 (CCL2) inflammatory chemokine. In the present work, we studied the effect of CCL2 contained in mesothelioma samples, particularly on monocyte recruitment. Then, we studied the fate of these monocytes in malignant pleural mesothelioma (MPM) PEs and their impact on tumor cells' properties.
METHODS: The implication of CCL2 in monocyte recruitment was evaluated using transmigration assays and a CCL2 blocking antibody. The phenotype of macrophages was determined by flow cytometry and enzyme-linked immunosorbent assay. Immunohistochemical analysis was used to support the results. Cocultures of macrophages with mesothelioma cells were performed to study cancer cell proliferation and resistance to treatment.
RESULTS: We showed that CCL2 is a major factor of monocyte recruitment induced by MPM samples. Macrophages obtained in MPM samples were M2 macrophages (high CD14, high CD163, and interleukin-10 secretion after activation). The colony-stimulating factor 1 receptor/macrophage colony-stimulating factor (M-CSF) pathway is implicated in M2 polarization, and high levels of M-CSF were measured in MPM samples compared with benign PE (4.17 ± 2.75 ng/mL and 1.94 ± 1.47 ng/mL, respectively). Immunohistochemical analysis confirmed the presence of M2 macrophages in pleural and peritoneal mesothelioma. Finally, we showed that M2 macrophages increased mesothelioma cell proliferation and resistance to treatment.
CONCLUSIONS: These results demonstrate the implication of CCL2 in MPM pathogenesis and designate M-CSF as a new potential biomarker of MPM. This study also identifies CCL2 and colony-stimulating factor 1 receptor/M-CSF as interesting new targets to modulate pro-tumorigenic properties of the tumor microenvironment.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCL2; M-CSF; Macrophages; Mesothelioma; Pleural effusions

Mesh:

Year:  2016        PMID: 27418105     DOI: 10.1016/j.jtho.2016.06.022

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  35 in total

1.  Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.

Authors:  Malik Hamaidia; Hélène Gazon; Clotilde Hoyos; Gabriela Brunsting Hoffmann; Renaud Louis; Bernard Duysinx; Luc Willems
Journal:  JCI Insight       Date:  2019-09-19

2.  Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: Self-amplifying immunosuppression in cancer.

Authors:  Saly Al-Taei; Josephine Salimu; Lisa K Spary; Aled Clayton; Jason F Lester; Zsuzsanna Tabi
Journal:  Oncoimmunology       Date:  2016-12-08       Impact factor: 8.110

3.  Novel immunotherapy clinical trials in malignant pleural mesothelioma.

Authors:  Zachary E Tano; Navin K Chintala; Xiaoyu Li; Prasad S Adusumilli
Journal:  Ann Transl Med       Date:  2017-06

Review 4.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

5.  Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.

Authors:  Pietro Bertino; Thomas A Premeaux; Tsuyoshi Fujita; Brien K Haun; Michael P Marciel; Fukun W Hoffmann; Alan Garcia; Haining Yiang; Sandra Pastorino; Michele Carbone; Toshiro Niki; John Berestecky; Peter R Hoffmann; Lishomwa C Ndhlovu
Journal:  Oncoimmunology       Date:  2019-04-17       Impact factor: 8.110

6.  Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients.

Authors:  Swati Khanna; Suzanne Graef; Francis Mussai; Gary Middleton; Carmela De Santo; Raffit Hassan; Anish Thomas; Neha Wali; Bahar Guliz Yenidunya; Constance Yuan; Betsy Morrow; Jingli Zhang; Firouzeh Korangy; Tim F Greten; Seth M Steinberg; Maryalice Stetler-Stevenson
Journal:  Clin Cancer Res       Date:  2018-03-30       Impact factor: 12.531

Review 7.  Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Authors:  Stefan Kiesgen; Leonardo Chicaybam; Navin K Chintala; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2017-10-26       Impact factor: 15.609

8.  Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma.

Authors:  Beatrice Dozin; Grazia Carbotti; Silvio Roncella; Paola Ferro; Paolo Dessanti; Pier Aldo Canessa; Silvano Ferrini; Marina Fabbi
Journal:  Cancer Immunol Immunother       Date:  2021-05-18       Impact factor: 6.968

9.  Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.

Authors:  Giulio Metro; Diego Signorelli; Elio G Pizzutilo; Laura Giannetta; Giulio Cerea; Miriam Garaffa; Alex Friedlaender; Alfredo Addeo; Martina Mandarano; Guido Bellezza; Fausto Roila
Journal:  Hum Vaccin Immunother       Date:  2021-05-18       Impact factor: 3.452

10.  Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.

Authors:  Silvia Mola; Giulia Pinton; Marco Erreni; Marco Corazzari; Marco De Andrea; Ambra A Grolla; Veronica Martini; Laura Moro; Chiara Porta
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.